Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.

Nature

Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, Cianfanelli V, Lorente M, Simoneschi D, Di Marco M, D'Acunzo P, Di Leo L, Rasmussen R, Montagna C, Raciti M, De Stefanis C, Gabicagogeascoa E, Rona G, Salvador N, Pupo E, Merchut-Maya JM, Daniel CJ, Carinci M, Cesarini V, O'sullivan A, Jeong YT, Bordi M, Russo F, Campello S, Gallo A, Filomeni G, Lanzetti L, Sears RC, Hamerlik P, Bartolazzi A, Hynds RE, Pearce DR, Swanton C, Pagano M, Velasco G, Papaleo E, De Zio D, Maya-Mendoza A, Locatelli F, Bartek J, Cecconi F.
PMID: 33854232
Nature. 2021 Apr;592(7856):799-803. doi: 10.1038/s41586-021-03422-5. Epub 2021 Apr 14.

Mammalian development, adult tissue homeostasis and the avoidance of severe diseases including cancer require a properly orchestrated cell cycle, as well as error-free genome maintenance. The key cell-fate decision to replicate the genome is controlled by two major signalling...

Cite
Maiani E, Milletti G, Nazio F, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592(7856):799-803doi: 10.1038/s41586-021-03422-5.
Maiani, E., Milletti, G., Nazio, F., Holdgaard, S. G., Bartkova, J., Rizza, S., Cianfanelli, V., Lorente, M., Simoneschi, D., Di Marco, M., D'Acunzo, P., Di Leo, L., Rasmussen, R., Montagna, C., Raciti, M., De Stefanis, C., Gabicagogeascoa, E., Rona, G., Salvador, N., Pupo, E., Merchut-Maya, J. M., Daniel, C. J., Carinci, M., Cesarini, V., O'sullivan, A., Jeong, Y. T., Bordi, M., Russo, F., Campello, S., Gallo, A., Filomeni, G., Lanzetti, L., Sears, R. C., Hamerlik, P., Bartolazzi, A., Hynds, R. E., Pearce, D. R., Swanton, C., Pagano, M., Velasco, G., Papaleo, E., De Zio, D., Maya-Mendoza, A., Locatelli, F., Bartek, J., & Cecconi, F. (2021). AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 592(7856), 799-803. https://doi.org/10.1038/s41586-021-03422-5
Maiani, Emiliano, et al. "AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity." Nature vol. 592,7856 (2021): 799-803. doi: https://doi.org/10.1038/s41586-021-03422-5
Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, Cianfanelli V, Lorente M, Simoneschi D, Di Marco M, D'Acunzo P, Di Leo L, Rasmussen R, Montagna C, Raciti M, De Stefanis C, Gabicagogeascoa E, Rona G, Salvador N, Pupo E, Merchut-Maya JM, Daniel CJ, Carinci M, Cesarini V, O'sullivan A, Jeong YT, Bordi M, Russo F, Campello S, Gallo A, Filomeni G, Lanzetti L, Sears RC, Hamerlik P, Bartolazzi A, Hynds RE, Pearce DR, Swanton C, Pagano M, Velasco G, Papaleo E, De Zio D, Maya-Mendoza A, Locatelli F, Bartek J, Cecconi F. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021 Apr;592(7856):799-803. doi: 10.1038/s41586-021-03422-5. Epub 2021 Apr 14. PMID: 33854232.
Copy Download .nbib Format: NLM
Lesion detection in 18F-sodium fluoride bone imaging: a comparison of attenuation-corrected versus nonattenuation-corrected PET reconstructions from modern PET-CT systems.

Nuclear medicine communications

Bebbington NA, Zacho HD, Holdgaard PC.
PMID: 34887371
Nucl Med Commun. 2022 Jan 01;43(1):78-85. doi: 10.1097/MNM.0000000000001487.

OBJECTIVES: An earlier study demonstrated comparable lesion detection between attenuation-corrected (AC) and nonattenuation-corrected (NAC) 18F-sodium fluoride (NaF) PET images, which is relevant for computed tomography (CT) radiation dose-saving. However, this finding may not be applicable to newer systems. The...

Cite
Bebbington NA, Zacho HD, Holdgaard PC. Lesion detection in 18F-sodium fluoride bone imaging: a comparison of attenuation-corrected versus nonattenuation-corrected PET reconstructions from modern PET-CT systems. Nucl Med Commun. 2022;43(1):78-85doi: 10.1097/MNM.0000000000001487.
Bebbington, N. A., Zacho, H. D., & Holdgaard, P. C. (2022). Lesion detection in 18F-sodium fluoride bone imaging: a comparison of attenuation-corrected versus nonattenuation-corrected PET reconstructions from modern PET-CT systems. Nuclear medicine communications, 43(1), 78-85. https://doi.org/10.1097/MNM.0000000000001487
Bebbington, Natalie Anne, et al. "Lesion detection in 18F-sodium fluoride bone imaging: a comparison of attenuation-corrected versus nonattenuation-corrected PET reconstructions from modern PET-CT systems." Nuclear medicine communications vol. 43,1 (2022): 78-85. doi: https://doi.org/10.1097/MNM.0000000000001487
Bebbington NA, Zacho HD, Holdgaard PC. Lesion detection in 18F-sodium fluoride bone imaging: a comparison of attenuation-corrected versus nonattenuation-corrected PET reconstructions from modern PET-CT systems. Nucl Med Commun. 2022 Jan 01;43(1):78-85. doi: 10.1097/MNM.0000000000001487. PMID: 34887371.
Copy Download .nbib Format: NLM
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.

Nature

Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, Cianfanelli V, Lorente M, Simoneschi D, Di Marco M, D'Acunzo P, Di Leo L, Rasmussen R, Montagna C, Raciti M, De Stefanis C, Gabicagogeascoa E, Rona G, Salvador N, Pupo E, Merchut-Maya JM, Daniel CJ, Carinci M, Cesarini V, O'sullivan A, Jeong YT, Bordi M, Russo F, Campello S, Gallo A, Filomeni G, Lanzetti L, Sears RC, Hamerlik P, Bartolazzi A, Hynds RE, Pearce DR, Swanton C, Pagano M, Velasco G, Papaleo E, De Zio D, Maya-Mendoza A, Locatelli F, Bartek J, Cecconi F.
PMID: 33854232
Nature. 2021 Apr;592(7856):799-803. doi: 10.1038/s41586-021-03422-5. Epub 2021 Apr 14.

Mammalian development, adult tissue homeostasis and the avoidance of severe diseases including cancer require a properly orchestrated cell cycle, as well as error-free genome maintenance. The key cell-fate decision to replicate the genome is controlled by two major signalling...

Cite
Maiani E, Milletti G, Nazio F, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592(7856):799-803doi: 10.1038/s41586-021-03422-5.
Maiani, E., Milletti, G., Nazio, F., Holdgaard, S. G., Bartkova, J., Rizza, S., Cianfanelli, V., Lorente, M., Simoneschi, D., Di Marco, M., D'Acunzo, P., Di Leo, L., Rasmussen, R., Montagna, C., Raciti, M., De Stefanis, C., Gabicagogeascoa, E., Rona, G., Salvador, N., Pupo, E., Merchut-Maya, J. M., Daniel, C. J., Carinci, M., Cesarini, V., O'sullivan, A., Jeong, Y. T., Bordi, M., Russo, F., Campello, S., Gallo, A., Filomeni, G., Lanzetti, L., Sears, R. C., Hamerlik, P., Bartolazzi, A., Hynds, R. E., Pearce, D. R., Swanton, C., Pagano, M., Velasco, G., Papaleo, E., De Zio, D., Maya-Mendoza, A., Locatelli, F., Bartek, J., & Cecconi, F. (2021). AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 592(7856), 799-803. https://doi.org/10.1038/s41586-021-03422-5
Maiani, Emiliano, et al. "AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity." Nature vol. 592,7856 (2021): 799-803. doi: https://doi.org/10.1038/s41586-021-03422-5
Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, Cianfanelli V, Lorente M, Simoneschi D, Di Marco M, D'Acunzo P, Di Leo L, Rasmussen R, Montagna C, Raciti M, De Stefanis C, Gabicagogeascoa E, Rona G, Salvador N, Pupo E, Merchut-Maya JM, Daniel CJ, Carinci M, Cesarini V, O'sullivan A, Jeong YT, Bordi M, Russo F, Campello S, Gallo A, Filomeni G, Lanzetti L, Sears RC, Hamerlik P, Bartolazzi A, Hynds RE, Pearce DR, Swanton C, Pagano M, Velasco G, Papaleo E, De Zio D, Maya-Mendoza A, Locatelli F, Bartek J, Cecconi F. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021 Apr;592(7856):799-803. doi: 10.1038/s41586-021-03422-5. Epub 2021 Apr 14. PMID: 33854232.
Copy Download .nbib Format: NLM
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma.

Clinical hematology international

Andersen KT, Hinge M, Szabo AG, Segel E, Ormstrup T, Holdgaard PC, Pallisgaard N, Kerndrup G, Plesner T.
PMID: 34595441
Clin Hematol Int. 2020 Jan 26;2(1):35-39. doi: 10.2991/chi.d.200116.001. eCollection 2020 Mar.

No abstract available.

Cite
Andersen KT, Hinge M, Szabo AG, et al. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clin Hematol Int. 2020;2(1):35-39doi: 10.2991/chi.d.200116.001.
Andersen, K. T., Hinge, M., Szabo, A. G., Segel, E., Ormstrup, T., Holdgaard, P. C., Pallisgaard, N., Kerndrup, G., & Plesner, T. (2020). Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clinical hematology international, 2(1), 35-39. https://doi.org/10.2991/chi.d.200116.001
Andersen, Kristian T, et al. "Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma." Clinical hematology international vol. 2,1 (2020): 35-39. doi: https://doi.org/10.2991/chi.d.200116.001
Andersen KT, Hinge M, Szabo AG, Segel E, Ormstrup T, Holdgaard PC, Pallisgaard N, Kerndrup G, Plesner T. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clin Hematol Int. 2020 Jan 26;2(1):35-39. doi: 10.2991/chi.d.200116.001. eCollection 2020 Mar. PMID: 34595441; PMCID: PMC8432336.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries